Oregon Therapeutics & Lantern Pharma Collaborate To Optimize Cancer Drug

 


Lantern Pharma Inc. (NASDAQ: LTRN) partners with Oregon Therapeutics to advance the development of XCE853, a pioneering PDI inhibitor, across various cancer types. Leveraging Lantern's RADR® AI platform, the collaboration aims to identify biomarkers and efficacy signatures, crucial for precision development and patient selection. This strategic alliance seeks to address the complexities associated with PDI inhibitors, offering a promising pathway to enhance cancer treatment strategies.

Oregon Therapeutics' CEO, Marc-Henry PITTY, underscores XCE853's preclinical efficacy and the potential for targeted development across multiple cancers. Through comprehensive molecular analysis powered by RADR®, the collaboration intends to uncover new insights into XCE853's therapeutic potential and its application in additional cancer indications. Panna Sharma, CEO of Lantern Pharma, emphasizes RADR®'s role in navigating the complexities of drug development, enabling informed decisions crucial for advancing XCE853 towards clinical success. With equal IP co-ownership, this collaboration marks a significant step towards pioneering AI-driven solutions in cancer therapeutics.

Read More - https://www.techdogs.com/tech-news/business-wire/oregon-therapeutics-lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853-a-potent-inhibitor-of-cancer-metabolism

Comments

Popular posts from this blog

Orlagh Neary, Former VP Of Quantum Ecosystem Engagement And GTM At Microsoft On Building Scalable And Safe AI And Quantum

Varun Srinivas Founder & CEO of Therix.ai and Co-Founder at Coditas on Building Real-World AI Solutions

MediaTek Vs. Snapdragon: Which Chipset Performs Better?